NCT04677660View on ClinicalTrials.gov

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Coronavirus Disease (COVID-19)
Interventions
BIOLOGICAL

TAK-919

TAK-919 intramuscular injection

BIOLOGICAL

Placebo

Placebo intramuscular injection

Trial Locations (2)

Unknown

Sumida Hospital, Sumida-ku

PS Clinic, Fukuoka

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04677660 - A Study of TAK-919 in Healthy Japanese Adults (COVID-19) | Biotech Hunter | Biotech Hunter